Depression
Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
Published in Health Business Week, April 3rd, 2009
Cephalon, Inc. (NASDAQ: CEPH) announced positive results from a phase two clinical trial of NUVIGIL(R) (armodafinil) Tablets [C-IV] as adjunctive therapy for treating major depressive disorder in adults with bipolar I disorder. An estimated two million American adults are affected by bipolar I disorder, which is characterized by fluctuations between extreme highs (manic) and lows (depressed) in mood. People with bipolar disorders cycle between periods of manic or depressive mood and typically spend more time in the depressed phase of the illness.
The eight-week, double-blind, placebo-controlled study evaluated the efficacy and safety of NUVIGIL (150 mg/day) as an...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2009-04-03)
More Articles from Health Business Week
- 1-800-FLOWERS.COM, Inc.
Raise Your Green Beer and Give a Cheer for St. Patrick's Day! - 118 Interactive Design
Michigan Autoworker Writes Song, 'Didn't Quit My Day Job, It Quit Me' - 1650 Broadway Associates Inc.
Searching for Miss Subways for Upcoming Reunion - 32nd Degree
Website Uses 'Crowdsourcing' To Help Businesses Name Their Products - 3M
3M Forms Strategic Relationship with ATL - 3M
Rugged New Cold Shrink Quick Splice from 3M Offers Added Protection for Low-Voltage Connections - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
